Trotz der Fortschritte der Schmerzforschung bilden Antidepressiva, Antikonvulsiva und lang wirksame Opioide nach wie vor die Basis jeder medikamentösen Therapie neuropathischer Schmerzen. Da einzelne neuropathische Krankheitsbilder keinen direkten Rückschluss auf die Wirksamkeit von Medikamenten im Allgemeinen bzw. spezieller Substanzen im Besonderen zulassen, müssen das bestmögliche Medikament oder die beste Kombination sowie die richtige Dosierung für jeden einzelnen Patienten zunächst durch Erprobung gefunden werden (individuelle Titration in Abhängigkeit von Wirkung und Nebenwirkungen). Eine zielgerichtete Therapie orientiert sich neben der zugrunde liegenden Schmerzentität und deren Symptomkonstellation insbesondere auch an den vielfach begleitenden Komorbiditäten wie Depression, Schlaf- und Angststörungen. Dabei muss eine differenzierte Pharmakotherapie immer auch in ein interdisziplinäres und multimodales Therapiekonzept eingebettet sein. Eine adäquate Schmerztherapie sollte so früh und so effektiv wie möglich eingeleitet werden, eine langfristige Therapiekontrolle ist unverzichtbar.
Despite the progress in pain research, antidepressants, anticonvulsants and long acting opioids still constitute the basis of any pharmacological treatment in neruopathic pain. Because the individual neuropathic conditions do not allow to draw direct conclusions regarding the efficacy of drugs in general or of specific drugs in particular, the best drug or best drug combinations including their appropriate doses must be found for the individual patient (individual dose titration considering efficacy and side effects). The goal of treatment addresses not only the underlying pain entity and its symptom constellation but also the improvement of comorbidities such as impaired mood, sleep, mobility, and physical functioning. It is emphasized that any individually tailored pharmacotherapy should be viewed within an interdisciplinary and multimodal treatment concept. Effective and timely analgesia at a therapeutic dose as well as long-term treatment follow-up are essential.
Key words
neuropathic pain - antidepressants - anticonvulsants - long acting opioids - individually tailored pharmacotherapy - multimodal treatment concept
Literatur
1
Attal N, Cruccu G, Haanpaa M. et al. .
EFNS guidelines on pharmacological treatment of neuropathic pain.
Eur J Neurol.
2006;
13
1153-1169
2
Baron R, Maier C..
Opioids in neuropathic pain.
Akt Neurologie.
2000;
27
332-339
3
Berman JS, Symonds C, Birch R..
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.
Pain.
2004;
112
299-306
4
Bernstein JE, Korman NJ, Bickers DR. et al. .
Topical capsaicin treatment of chronic postherpetic neuralgia.
J Am Acad Dermatol.
1989;
21
265-270
5
Bruehl S, Harden RN, Galer BS. et al. .
External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria. International Association for the Study of Pain.
Pain.
2001999;
81
147-154
6
Collins SL, Moore RA, McQuay Hj, Wiffen P..
Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review.
J Pain Symptom Manage.
2000;
20
449-458
7
Eisenberg E, McNicol E, Carr DB..
Opioids for neuropathic pain. Cochrane Database Syst Rev.
2006;
3
8
Eisenberg E, McNicol ED, Carr DB..
Efficacy of mu1z-opioid agonists in the treatment of evoked neuropathic pain: systematic review of randomized controlled trials.
Eur J Pain.
2006;
10
667-676
9
Finnerup NB, Otto M, McQuay HJ. et al. .
Algorithm for neuropathic pain treatment: An evidence based proposal.
Pain.
2005;
118
289-305
10
Finnerup NB, Sindrup SH, Bach FW. et al. .
Lamotrigine in spinal cord injury pain: a randomized controlled trial.
Pain.
2002;
96
375-383
11
Freynhagen R, Baron R, Gockel U, Tolle TR..
painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain.
Curr Med Res Opin.
2006;
22
1911-1920
12
Freynhagen R, Busche P, Konrad C, Balkenohl M..
Wirksamkeit und Wirkungsbeginn von Pregabalin bei Patienten mit neuropathischen Schmerzen.
Schmerz.
2006;
20
90-92
13
Freynhagen R, Muth-Selbach U, Lipfert P. et al. .
The effect of mirtazapine in patients with chronic pain and concomitant depression.
Curr Med Res Opin.
2006;
22
2257-2264
14
Freynhagen R, Vogt J, Lipfert P, Muth-Selbach U..
Mirtazapine and its enantiomers differentially modulate acute thermal nociception in rats.
Brain Research Bulletin.
2006;
69
168-173
15
Fromm GH, Terrence CF, Chattha AS..
Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up.
Ann Neurol.
1984;
15
240-244
16
Gilron I, Bailey JM, Tu D. et al. .
Morphine, gabapentin, or their combination for neuropathic pain.
N Engl J Med.
2005;
352
1324-1334
17
Goldstein DJ, Lu Y, Detke MJ. et al. .
Duloxetine vs placebo in patients with painful diabetic neuropathy.
Pain.
2005;
116
109-118
18
Kalso E, Edwards JE, Moore RA, McQuay HJ..
Opioids in chronic non-cancer pain: systematic review of efficacy and safety.
Pain.
2004;
112
372-380
19
Karst M, Salim K, Burstein S. et al. .
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.
JAMA.
2003;
290
1757-1762
20
Morrison RS, Meier DE..
Clinical practice. Palliative care.
N Engl J Med.
2004;
350
2582-2590
21
Moulin DE, Clark AJ, Gilron I. et al. .
Pharmacological management of chronic neuropathic pain - Consensus statement and guidelines from the Canadian Pain Society.
Pain Res Manag.
2007;
12
13-21
22
Capsaicin Study Group .
Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy.
Diabetes Care.
1992;
15
159-165
23
Otto M, Bak S, Bach FW. et al. .
Pain phenomena and possible mechanisms in patients with painful polyneuropathy.
Pain 2003.
2003;
101
187-192
24
Rowbotham MC, Davies PS, Verkempinck C, Galer BS..
Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia.
Pain.
1996;
65
39-44
25
Rowbotham MC, Goli V, Kunz NR, Lei D..
Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study.
Pain.
2004;
110
697-706
26 Saarto T, Wiffen PJ.. Antidepressants for neuropathic pain. Cochrane Database. Syst Rev 2005
27
Sandkuhler J, Kress HG..
Opioids for chronic nonmalignant and neuropathic pain. Eur.
J Pain.
2005;
99
99-100
28
Sindrup SH, Jensen TS..
Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.
Pain.
1999;
83
389-400
29
Svendsen KB, Jensen TS, Bach FW..
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
BMJ.
2004;
329
30
Vestergaard K, Andersen G, Gottrup H. et al. .
Lamotrigine for central poststroke pain: a randomized controlled trial.
Neurology.
2001;
56
184-190
31
Wernicke JF, Pritchett YL, D'Souza DN. et al. .
A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
Neurology.
2006;
67
1411-1420
32
Ziegler D..
Treatment of diabetic polyneuropathy: Update 2006.
Ann N Y Acad Sci.
2006;
1084
250-266
33
Ziegler D, Nowak H, Kempler P. et al. .
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis.
Diabet Med.
2004;
21
114-121
Korrespondenz
Priv.-Doz. Dr. Rainer FreynhagenD.E.A.A.
Ambulanz für Schmerztherapie und Palliativmedizin
Klinik für Anästhesiologie, Universitätsklinikum Düsseldorf
Moorenstraße 5
40225 Düsseldorf
Email: freynhagen@med.uni-duesseldorf.de